ExploreWatchlistsPricing
  1. JP-listed companies
  2. RaQualia Pharma Inc.
  3. Financials
  4. Cash and cash equivalents

RaQualia Pharma Inc. (4579)

Market cap
¥11.9B
P/E ratio
-177.9x
Rakuoria Drug Discovery develops new pharmaceutical compounds through early-stage research and clinical trials, then licenses them to major pharmaceutical companies for revenue.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 20253,241-2.97%
Dec 31, 20243,340-10.09%
Dec 31, 20233,715+1.08%
Dec 31, 20223,675+56.72%
Dec 31, 20212,345+68.23%
Dec 31, 20201,394-35.88%
Dec 31, 20192,174+30.09%
Dec 31, 20181,671-26.31%
Dec 31, 20172,268+58.85%
Dec 31, 20161,428-22.41%
Dec 31, 20151,840-2.69%
Dec 31, 20141,891

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat